SCHEMBL704571

SCHEMBL704571

CC(C)(C)OC(=O)N1CC(OCc2ccccc2)CC1(C)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
KLK7 P49862 1/20 0.40
GPR119 Q8TDV5 2/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
STS P08842 1/20 0.38
RORC P51449 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
BACE1 P56817 1/20 0.36
BACE2 Q9Y5Z0 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
CHRM3 P20309 1/20 0.36
USP30 Q70CQ3 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043429 1.00 ABCB1 (0.41) ABCB1JAK2JAK1KLK7GPR119
SCHEMBL27223224 1.00 ABCB1 (0.41) ABCB1JAK2JAK1KLK7GPR119
SCHEMBL7107445 0.90 RORC (0.41) ABCB1GPR119RORCALDH1A1BACE1
SCHEMBL27380345 0.90 ABCB1 (0.43) ABCB1KLK7ALDH1A1
SCHEMBL7107448 0.90 RORC (0.41) ABCB1GPR119RORCALDH1A1BACE1
SCHEMBL6770180 0.90 RORC (0.41) ABCB1GPR119RORCALDH1A1BACE1
SCHEMBL27380338 0.90 ABCB1 (0.43) ABCB1KLK7ALDH1A1
SCHEMBL5151803 0.87 ABCB1 (0.41) ABCB1JAK2JAK1KLK7GPR119
SCHEMBL3305393 0.86 CHRM3 (0.35) ABCB1JAK2JAK1KLK7STS
SCHEMBL2426349 0.85 NAAA (0.38) ABCB1CTSBCTSKRORCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059806-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2024-03-21 WO disclosed
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 ABCB1 285/4885JAK2 2870/4885JAK1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.